Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Asciminib→

Asciminib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1492952-76-7
Molecular formula
C20H18ClF2N5O3
Molecular weight
449.8 g/mol
Drug class
STAMP inhibitorallosteric BCR::ABL1 tyrosine kinase inhibitor
Mechanism of action
Binds the myristoyl pocket of the ABL1 kinase domain (STAMP mechanism), allosterically inhibiting BCR::ABL1 kinase activity, including activity of many mutant forms. It acts at a site distinct from the ATP-binding pocket targeted by conventional tyrosine kinase inhibitors.
Indications / reported uses
  • Treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) in adults with product-specific prior-treatment or mutation criteria; consult current US and EMA product information for exact lines of therapy

Sources: US DailyMed — SCEMBLIX (asciminib) · NCI Drug Dictionary — Asciminib · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Asciminib Environmental Risk Assessment (ERA) (the Asciminib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.